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Abbreviation 
 
SRM   Small renal mass 
RMS:   Renal mass biopsy 
IGB:    Image guided biopsy 
RFA:   Radiofrequency ablation 
AML:   Angimyolipoma 
RCC:   Renal cell carcinoma 
US:    Ultrasound 
MRI:   Magnetic resonance imaging 
CT:    Computer tomography 
FISH:   Flourescent in situ hybridisation 
DNA:   Deoxy ribonucleic acid 
VEGF  Vascular endothelial growth factor 
VHL   Von hipple Lindu 
FNAC  Fine needle aspiration cytology 
IHC    Immunohistochemistry 
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ABSTRACT 
 
 
 
TITLE OF THE ABSTRACT : To study the role of image guided biopsy in the   
        management of T1 renal masses 
 
DEPARTMENT   : GENITOURINARY SURGERY 
 
NAME OF THE CANDIDATE : AMIT VIJAY DESHPANDE 
 
DEGREE AND SUBJECT  : M Ch UROLOGY 
 
NAME OF THE GUIDE  : Dr NITIN S KEKRE 
 
AIM / OBJECTIVES:  
 
The aim of our study was to compare imaging guided biopsy outcome with final 
histopathological outcome .We aimed to calculate sensitivity, specificity positive predictive 
value, accuracy in determining the diagnosis. 
MATERIAL AND METHODS: 
 We included all patients with renal mass <= 7 cm. We excluded patients with metastatic 
disease, patients who are not willing, with deranged coagulation profile and tumour > than 7 
cm. Patients underwent image guided percutaneous renal mass biopsy. Post biopsy patients 
were monitored at regular interval to rule out any occult bleed, trauma to surrounding organs. 
The patients were provided analgesics as per need. Irrespective of the biopsy report these 
patient underwent surgery. The pathological characteristic of the biopsy and the 
histopathological specimen were compared on the basis pathological finding (malignant/benign 
lesion), in case of malignancy Furhann’s classification. 
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RESULTS:  
  Out of 25 biopsies, 20 biopsies showed RCC, this corresponded with final histological 
outcome. 3 patients were reported to have hybrid oncocytolytic variant; 2 patients had 
oncocytoma and the third one had chromophobe RCC.  2 samples were inadequate for 
interpretation; the final histopathology revealed lipid poor angiomyolipoma and clear cell RCC. 
Sensitivities, specificities, PPVs, and NPVs for the detection of malignancy by core biopsy are 
92%, 100%, 10%, 33% respectively. The accuracy of the core biopsy is 100% however the 
accuracy for the differentiation of Fuhrman grade was 76%. 
CONCLUSIONS: 
 The role of RMB in the setting of T 1 renal masses is expanding. Approximately 12% of 
renal masses removed by surgical excision have benign pathology hence surgery can be safely 
differed if we know pathology beforehand using IGB. It has high sensitivity, specificity and 
accuracy in detecting histology of renal masses. The specific and negative predictive values are 
100% and 66% relatively. Post procedure complications are relatively uncommon, encouraging 
us for its wider adoption.  
Key words: Image guided biopsy, T1 renal masses, final histology, Sensitivity, specificity 
 
 . 
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Introduction 
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In the last 20 yrs there is 2% annual increase in the incidence of renal cell carcinoma 
(RCC) has been observed both in Europe and in North America (1–3).The increasing incidence of 
RCC has occurred across all clinical stages, but the greatest increase has been observed in the 
incidence of localized tumors. Most of these patients were diagnosed incidentally during 
imaging for nonspecific abdominal or musculoskeletal complaints or follow-up of other 
unrelated malignancies(4). 
A SMALL RENAL MASS is generally defined as a contrast-enhancing mass within the 
kidney with the largest dimension of up to 4 cm(4)(5) . In more recent years, 48 to 66% of RCCs 
have been detected incidentally as SRMs in asymptomatic patients, whereas historically most 
cases were diagnosed following investigations for flank pain or hematuria(6).  The largest 
increase in incidentally detected renal tumors has occurred among patients aged 70–89 years, 
presumably because these individuals are more likely to undergo radiologic examination for 
other medical issues (7). Tumor size at diagnosis has also decreased substantially over time. 
(8,9) 
The standard of care for small localized renal neoplasms is partial or radical 
nephrectomy. Progress in technology has recently led to effective minimally invasive surgical 
approaches for renal tumour excision, including laparoscopy and robotic assisted surgery. 
Those patients who are deemed surgically unfit can be considered for other non surgical 
approaches like cryo ablation, radio frequency ablation, HIFU  or microwave therapy. 
However, the histologic features of SRMs are heterogeneous. Frank et al(10)  observed 
that as tumor size decreases there is a significant increase in the likelihood of a benign 
histology, a papillary compared to a clear-cell histology and a low-grade compared to a high-
Page | 11  
 
grade malignancy. In their experience, 30% of tumors below 4 cm in their maximum dimension 
were benign and over 87% of those diagnosed as clear-cell RCCs were low-grade tumors. A very 
few small renal tumours harbour aggressive disease. An analysis of the Surveillance 
Epidemiology and End Results (SEER) database from 1998 to 2003 showed a 5.2% prevalence of 
metastasis at presentation among 8792 patients with RCCs _4 cm, with an increase of 
metastasis by 3.5% for each 1-cm increase in tumour size(11).  On the other hand, 
approximately 20–25% of radiologically suspicious SRMs are benign.  Although most contrast-
enhancing renal masses are malignant, CT or MRI features fails to conclusively differentiate 
RCCs from benign tumours such as oncocytomas “low fat” angiomyolipoma.(12,13) . Moreover, 
a significant proportion of histologically confirmed RCCs are low-grade tumours with relatively 
indolent biologic and clinical behaviour (7,9).  
These observations have led to the development of alternative treatment options for 
selected patients with medical co-morbidities, including minimally invasive ablative therapies 
and active surveillance (AS).However measuring the growth rate of lesions using serial 
radiographies has also been insufficient to predict the true natural history of renal  
 As a consequence, biologic data are needed to assess the natural history of either 
untreated renal masses under active surveillance or when energy ablative techniques. Today, 
the challenges in the adequate diagnosis and treatment of small renal tumors include the 
identification of tumors with less aggressive potential, treating less aggressive tumors less 
invasively and certifying tumor control after less invasive therapy. To this end, image-guided 
biopsy could provide information that may be helpful when deciding on the most appropriate 
management strategy for these patients. 
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Aims and 
objectives 
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 The selective use of percutaneous biopsy for diagnosis in renal masses is a relatively 
uncommon approach when compared to the management of other solid neoplasms. With 
recent advancements in imaging techniques and their widespread use, the internist tumour has 
gone a paradigm shift and now called as radiologist’s tumour. Incidental discovery of 
asymptomatic, small renal masses (SRM) is on the rise and a substantial percentage of these 
SRM are benign. Recent advances in diagnostics have significantly improved accuracy rates of 
renal mass biopsy (RMB), making it a potentially powerful tool in the management of SRM. 
RMB may offer important information enabling treating clinicians to better risk-stratify patients 
and ultimately provide a more personalized treatment approach for T1 renal masses.  
The aim of our study was to compare imaging guided biopsy outcome with final 
histopathological outcome like pathological finding (malignant/benign lesion), in case of 
malignancy Furhann’s grade. We aimed to calculate sensitivity, specificity positive predictive 
value, accuracy in determining the diagnosis. 
Secondary outcome includes assessing the complication secondary to IGB and stratifying 
then between minor and major complications. We also wish to see if the nephrometry score 
bears any outcome on biopsy. 
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Review of 
literature 
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Over the last two decades, there is increase in incidence of kidney cancer worldwide. 
Renal cancers are responsible for 2% of all the cancer deaths in the US.  This is partially due to 
the increasing use of non invasive abdominal imaging techniques such as US, CT and MRI. 
Moreover, with advances in the current imaging modalities this detection of tumour occur at 
very early stage (1, 2). It is estimated that renal mass is incidentally detected in around 13–26% 
of abdominal imaging studies. As the incidence of both benign and malignant lesions has 
increased, at the same time there is decrease in tumor size at the time of detection(6,16). They 
are usually associated with improved survival and only some of them could be potentially 
threatening (6, 9). 
 Usually simple cysts and angiomyolipomas [AML] can be diagnosed radiographically, 
however, many renal masses, including oncocytomas (9), atypical AML (7) and most RCC (7, 13) 
are not easily distinguishable on imaging and final diagnosis depends upon histopathological 
examination. 
Presently the standard of care for such masses is either partial nephrectomy or radical 
nephrectomy. Early surgical intervention is justified to prevent tumour progression and 
improved survival. Nephron-sparing surgery is preferred as compare to radical nephrectomy for 
smaller RCCs, as it gives equivalent cancer-control rate and reduced progression to chronic 
kidney disease (14,17).At present partial nephrectomy is considered the treatment of choice for 
majority of clinical T1 renal masses, even in those with a normal contralateral kidney (18). With 
the advances in the field of minimally invasive surgery, laparoscopic and robotic partial 
nephrectomy, have achieved equivalent oncologic outcomes and have improved morbidity 
profile.  
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However, despite aggressive surgical resection the is hardly any change in mortality 
rates (19). Natural history of SRM has shown that these groups of patients have heterogeneous 
disease process. They have different histological subtype and aggressiveness.  Only 20% of the 
lesions  are potentially aggressive, 20%  have benign histology, while  the rest  60% represent 
indolent RCC (20, 21). Hence active surveillance was proposed as one of the option in 
management of SRM. Initially this approach was considered only for the patients with 
significant co-morbidities who are unfit for surgical intervention or elderly patients. Even 
though the studies on active surveillance have shown that there no progression to metastatic 
disease, the mean follow up in all these studies was short and hence for further validation  long 
duration follow-up is needed(22, 23). 
 It was proposed that tumor growth rate can be a useful tool to assess the 
aggressiveness of tumour. But the natural history of SRM has shown that growth rate is very 
slow with only small proportion of these tumours grow significantly over time. 
With the advent of RFA or cryo ablation, these patients can also be considered for 
minimal invasive intervention. However, there is a small but definite risk of tumor progression 
and metastasis. 
Till last decade, the utilization of renal mass biopsy (RMB) for diagnosis of renal masses 
is a relatively uncommon approach when compared to management of other neoplasms. In 
most other solid tumors, obtaining a biopsy is one of the first steps in management algorithm. 
Historically, renal mass biopsy has been reserved for a limited number of indications like 
metastatic disease, infection, and lymphoma (24). However in the recent past, there is 
resurgence of renal mass biopsy (RMB). Biopsy using thin needles [20 gauge or thinner] has 
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been shown to be accurate in the diagnosis of renal masses (25,26) due to advances in 
cytological techniques (27–31) and in some cases, determination of subtype of RCC and nuclear 
grade(27,30). 
. 
Technical Considerations 
Imaging modality for RMB 
 RMB is usually done under image guidance either ultrasound [US], or computed 
tomography [CT] or a combination of the two. Each technique has its own distinct advantages 
in relation to tumor site, body habitus and other important considerations. The primary 
advantages of ultrasound guided biopsy are; it can be done under real time with multiplanar 
imaging ,it is cheap, portable and does not involve any ionizing radiations (3, 32).  
However US may fail to differentiate isoechoic renal masses from normal renal 
parenchyma, distinguishing adjacent pleura and hollow viscera. And technical difficulties 
include performing biopsy in the obese population. (33) 
This phenomenon could explain the high failure rate in small tumors. He suggested use 
of CT fluoroscopy during biopsy of such masses. 
Recent advances in software and instruments allow fusion of prior CT or MR imaging to 
real-time US images. This combines the benefits of each modality and overcome some of the 
shortcoming of individual imaging (36). However , more studies are needed for validation of the 
technology(36).MRI can also be used to guide IGB,  mostly before MRI guided thermal 
therapy(37). 
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Technique of FNAC/ IGB 
Fine needle aspiration cytology 
 FNAC is done using mechanical disruption and suction pressure which theoretically 
produce more cellular samples than biopsy. Zajelda’s technique uses fine needle capillary 
technique without suction. It  results in fewer cellular smears (42). Samples can  also be used to 
prepare cell blocks that can be used to perform specialized tests such as 
immunohistochemistry, FISH, and cytometric techniques(35). Cytopathologist is always 
required to assess sample quality and rapid handling of sample to avoid coagulum formation as 
it can affect the sample reporting. Skills of the cytologist is a major factor that determines 
diagnostic accuracy of FNA (33,43), and is mostly considered to be lower than IGB(35). Schieven 
LW et al (44) have showed that the processing technique has impact on the accuracy rates. 
Recent studies have shown that the  diagnostic accuracy of FNA is reaching as high as 100% for 
malignant neoplasm and 92% for histological subtype(35). Masoom S et al (40) have reported 
an excellent concordance between FNAC and the final surgical pathology. 
 
Core biopsy 
Renal mass biopsy has its distinct advantages over cytology.  Majority of the studies 
using the large and fine needles do not assess the performance of needle individually. Thinner 
needles [20 gauge or more] reduces the risk of infection, hemorrhage; even if the needle path 
passes through the hallow viscera or vascular organs, or the patient has impaired coagulation. 
By default, FNA techniques use fine needles [21 gauge or smaller].It reduces blood 
contamination and maximize cell yield. Fine needle aspiration is safer when there is possibility 
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that the biopsy tract might pass through bowel or vascular organ. The processing of sample is 
quicker and allows early determination of adequacy of  sampling(38,39).  In absence of proper 
RCT, most authors advise to use 18-gauge needle in order to improve the biopsy yield without 
increasing the procedure related morbidity (24). Breda et al in its  ex vivo biopsy and 
Schmidbauer in its in vivo study (34)  found that an 18-gauge needle was most accurate in 
determining histological diagnosis (45).  
IGB requires fixation and pathological processing, which usually takes longer time. A 
frozen section may be considered but it requires specialised staff. It also has limitations with 
respect to accuracy (38). 
Use of coaxial guide or cannula is advised while performing core biopsy. Use of coaxial 
guide  at the extra thoracic site has reported a significant increase in the biopsy outcome 
without  increase in morbidity (40). The coaxial technique allows multiple needle insertion of 
biopsy needle through the mass with only one pass through the intervening normal tissues. It 
minimises the chance of needle tract seedling, decreases patient’s distress and reduces 
procedure time. The coaxial cannulas are easily seen on imaging than conventional needles. 
(41). 
 For tumors <4 cm, at least 2 biopsies from both the central and peripheral regions are 
recommended. For tumours more than 4 cm, two to three peripheral biopsies are advocated 
especially in the presence of central necrosis.  Adequate core length recommended   is at least 
1cm (35). Each Core should be looked for size and quality. If the core appears small [<1 cm] or 
fragmented, an additional biopsy should be taken (35). Samples for DNA expression microarrays 
or  genomic hybridization can be obtained (36). 
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 Studies comparing the outcome of IGB with FNA have shown that FNA had a high rate of 
non-diagnostic samples and required an experienced cytopathologist for interpretation (34). 
 Core biopsies and fine needle aspiration appear to be interrelated. In complex cystic 
masses, biopsy taken from suspicious  solid areas are likely to improve the diagnostic accuracy 
of FNA alone (24, 51). Soft, high grade tumors often provides high tissue yield during FNA 
because of use of negative pressure. But core biopsy is difficult because the tumor does not gel 
together to allow needle extraction. Wood et al (8) have reported 95% accuracy and 93% 
sensitivity for malignancy using a combination of both FNA and IGB. 
 In summary, although IGB is considered to give more accurate information in most 
studies, FNA can be additive to IGB and has distinct advantages in certain clinical settings. 
 
Accuracy and false-negative results 
 Accuracy is defined as the percentage of positive biopsies for which the pathological 
diagnosis appeared to be correct; based either on the final surgical pathology or imaging 
surveillance. This definition is not fully correct because it considers that imaging surveillance is 
accurate. In a recent meta analysis by Lane et al (48), the “diagnostic accuracy” of IGB for 
cancer was reported to be increasing from an average of 82% before 2001 to 90% between 
2001 and 2006 and recently reported to be  more than 95% (40,49,50). 
 The sensitivity is defined as ratio of the number of malignancies identified by IGB to the 
total number of malignancy. The diagnostic accuracy of IGB as reported in literature ranges 
from 93 to 100 % [Table 2] whiles the sensitivity varies from 84% to 100% [Table 2]. Sensitivity 
is less than “accuracy”, because it takes into consideration negative biopsies.  
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 Most of these studies have reported very low false-positive rate (34, 49, 53, 54, 55) 
which implies that a diagnosis of malignancy on IGB can be mostly accurate and most of the 
time will match with final surgical pathology. In a study by Liu et al (28), the reported negative 
predictive value was approximately 80–90%. However, limited data is available on the negative 
predictive value as most of the studies are on active surveillance or patients with a benign 
tumour on IGB will not undergo surgery. Similarly, the data on specificity of results of IGB is also 
limited due to absence of surgical confirmation in many studies. 
 The issue of non informative biopsies is one of the subjects of concern. Biopsy failure 
represents that biopsy in which the tumor tissue could not be retrieved. Indeterminate 
biopsies included cases in which tumor tissue was retrieved, but it is inadequate for the 
pathologist to make final conclusion. 
 To standardize reporting, all biopsies are classified into four basic categories; non 
informative or and informative biopsy. The informative includes those that are confirmed 
accurate, presumed accurate or confirmed inaccurate.   
 In summary IGB is trust worthy owing to high sensitivity and positive predictive value of 
IGB and the low false negative rates. However, the major drawback includes sampling error, 
tumor heterogeneity, and presence of “oncocytic neoplasm” continues to exist. Thus, around 
10–20% of all IGB may still represent non-informative and have to be handled cautiously. 
 
Non informative biopsy: 
 It includes both biopsy failure and indeterminate biopsies. The average rate of non 
conclusive biopsies has been around 10–20%.  In the past, many non-conclusive biopsies which 
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were inaccurately considered as “false-negative” were actually inappropriate biopsy. Patients 
with non-conclusive biopsy can undergo repeat biopsy or surgical extirpation. 
 The rate of indeterminate biopsies is affected by inter observer variation of pathologist 
and their ability to assess the amount of material required for diagnosis.  Dechet et al(60) 
reported zero failure rate  but he also observed  the rate of  indeterminate discordant  biopsy 
for the two pathologists were 11 and 17%. For the IGB, the rate of biopsy failure ranged from 8 
to 16% and the rate of non-informative biopsy ranged from 0 to 8% (40).  
 Definition of diagnostic and non diagnostic biopsies is different in different studies. In 
Some studies reported biopsies containing normal kidney or fibrous tissue as diagnostic and 
classified as  the benign result (50), whereas in others, they are considered as indeterminate. So 
to standardize the reporting of IGB Shannon et al (61) has proposed a strict criteria for a non-
diagnostic biopsy. 
A biopsy is considered non-diagnostic when either there is insufficient material for 
analysis or sample have only normal renal parenchyma or fat or fibro-fatty connective tissue or 
necrotic tissue or a blood clot or with only inflammatory or fibrotic tissue. 
 Frequently, the sample classified as non-diagnostic biopsies contains normal renal 
parenchyma. The literature has shown that if repeat biopsy or surgery is performed on such 
patients most of then turn out to be malignant lesion [Table 1].As seen below about half of the 
patient with non diagnostic biopsy underwent surgery or re biopsy and about 66% of then turn 
out to be malignant lesion.  
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Table 1 
 
Series No. of biopsies Nondiagnostic biopsies Re-biopsy/surgery Malignancy 
Volpe et al (49) 100 16 non diagnostic 2 re biopsy 1 RCC 
Schmidbauer et al 
(34) 
70 9 non diagnostic 1 re biopsy 
5 surgery 
1 RCC 
3RCC 
Lechevallier et al. 
(24) 
73 15 4 Re biopsy 
3 Surgery 
3 RCC 
3 RCC 
Neuzellet et al(35) 88 3 Failed 
5 inconclusive 
2 Surgery 
3 surgery 
2RCC 
3 RCC 
Shannon et al(61) 235 50 non diagnostic 12 Re biopsy 
10 Surgery 
5Rcc+1TCC 
7Rcc+1TCC 
 
Diagnostic and confirmed accurate biopsy 
 These include either confirmed-positive or confirmed negative biopsies, which have 
been proven by surgical excision. They represent expected outcome form IGB [Table2]. 
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Table 2 
Reference 
No. 
No. 
tumo
rs 
biopsy 
failure 
(%) 
No. 
indeterminate 
(%) 
No. biopsy 
non-
informative 
(%) 
No. false 
negatives 
(%) 
No. false 
positives 
(%) 
 
No. accurate/Total No. (%) Sensitivity 
for 
malignancy 
(%) 
       Malignant 
vs benign 
Histology Grade  
Vasudevan 
et al. (2006) 
(52) 
100 NA NA 29(29%) 0 0 71/71 
(100) 
44/44 
(100)  
NA 43/51(84.3%) 
Beland et 
al.(2007) 
 (53) 
58 3(5.2) 3(5.2) 6 (10.4%) 1 (1.9%) 0 51/52 
(98%) 
NA NA 38/39(97.4%) 
Schmidbauer
et al. (2008) 
(34) 
78 0 2 (3%)   2(3%) 3 (3.8%) 0 73/76 
(96.1%) 
59/60 
(98.3%) 
44/58 
(76%) 
60/65 
(92.3%) 
Volpe et al. 
(2008) (49) 
 
100 8 (8%) 8 (8%) 16 (16%) 0 0 84/84 
(100%) 
56/60 
(93%) 
for RCCs 
41/60 
(68%)  
66/67 
(98.5%) 
Masoom et 
al. (2009 )     
( 55) 
  
31 0 0 0 0 1 (3.2%) 
 
30/31 
(96.7%) 
28/29 
(96.6%) 
NA 28/28 (100%) 
 
 
Informative but proven inaccurate 
 In these samples the diagnosis on the biopsy does not match with final outcome. This 
group represents both false-negative and false-positive results, and is considered worrisome for 
clinicians. In the recent studies, the proportion of these cases was less than 1 % [Table 2]. False-
negative results are of concerns, since those patients with presumed benign lesion may be lost 
to follow up and there is chance of spread of malignancy. The most common reasons y are the 
sampling error and tumor heterogeneity(53).  Gupta et al have reported a lower sensitivity of 
56% and a higher rate of biopsy failure in small masses owing to the technical difficulty in 
targeting these lesions (29).In larger tumors it can be because of  the presence of central 
necrosis(29, 54). Most renal masses are known to demonstrate a varied degree of tumor 
Page | 25  
 
heterogeneity usually up  to 25%, thus complicating the situation even further(55,56,57). 
Finally, there exists interobserver and intraobserver variability amongst pathologists which 
complicates the picture (46, 47). 
 
Informative and presumed true 
 The lesion is differentiated as a benign lesion from a malignant one; however lack 
pathological confirmation. This group represents of about approximately 20–37% of all cases as 
shown in table 2. Most of the patients with IGB showing benign lesion were managed with close 
surveillance with clinical examination and radiological investigations. However, without a 
comparable surgical histology, this presumed diagnosis cannot be authenticated. In a study by 
Schmidbauer et al, 78 patients with renal masses underwent biopsy and then subsequent 
surgical excision. 21 patients had a benign diagnosis on biopsy (34), however after the final 
histology, 3 patients were found to have a malignant tumour thus representing false-negative 
result. “Oncocytic neoplasms” on IGB needs special mention as typically they were considered 
to be benign at many centers. But this group comprises of both benign and malignant lesion 
and requires special immunohistochemical markers for further differentiation. Thus, the final 
management of a patient with a lesion with a benign biopsy result will depend on the multiple 
factors such as radiographic appearance of the lesion, patients’ age, co morbidities and 
patient’s preference. 
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Accuracy of tumor grade and subtype 
 
 Fuhrman grading of RCC is classified on the basis of nuclear size, shape, and nucleolar 
prominence. In spite of its widespread use, the prognostic significance and reproducibility have 
also been questioned. Most pathologists depend upon assessment of nucleolar prominence 
alone while grading renal cell carcinoma. Delahunt B  et al (111) have shown that worst the 
nucleolar grade, worst is the outcome in relation to aggressiveness of cancer. 
 With increasing sophistication of IGB, there has been renewed attention to Fuhrman 
grading of biopsies, so as stratify tumor risk behaviour. In literature, for Fuhrman nuclear grade 
the similarity between the IGB specimens and  post op histopathology range from 45% to 90%, 
although most discordant cases off by only one grade(33, 34, 54, 58).  In the Lebret study, by 
classifying the lesion into “low” and “high” grade, he has increased the concordance rate to as 
high as 76%. This difference in the concordance is because of both interobserver variability and 
tumor heterogeneity. The significance of this concordance may be more relevant in the setting 
of management of these patients with active surveillance or minimally invasive ablative 
therapies, which are relatively contraindicated for a high-grade cancer, regardless of size(59).  
Similarly accuracy for identifying the histological subtype ranges from 87–100% (27).   
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Complications: 
 Complications after the imaging guided biopsy need special mention. The Society of 
Interventional Radiology has classified biopsy complications into minor and major categories 
depending on patient’s outcome. Minor complications are those in which patient required no 
or nominal therapy in the form of overnight hospital admission for observation only. Minor 
complication of image guided biopsy includes biopsy site pain or localized skin hematoma. 
 Major complications are defined as those which require treatment or longer 
hospitalization, or lead to permanent adverse outcome or death. Most of these studies on IGB 
and FNA showed few or no major complications (62). The most common complication 
encountered is bleeding, which is usually subclinical and detected on CT scan during follow up 
with self-limiting treatment. Tang et al have reported bleeding rates of 91%, however, major 
bleeding requiring transfusion or hospital observation occurred in only 1.5% of cases (62). 
 Although theoretically it is believed that larger-needle biopsies (18 gauge or less) are 
associated with higher risk of bleeding complications than with smaller-needle biopsies (20 
gauge or more), published studies showed  no significant difference in bleeding complications 
based on needle size(8). 
 Other differential diagnosis for persistent bleeding is arteriovenous fistula. This 
complication rate varies from 1.5–16% of cases (62, 63). However, a majority of these are self-
limiting and clinically insignificant. Majority of arteriovenous fistulae resolve on their own in a 
period of 3.5–20 months without any intervention (63). The remaining may present with  
clinical symptoms such as hematuria, hypertension or alteration in kidney function and are 
usually managed with angioembolization (64).  
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 Pneumothorax can develop as a result of biopsy of upper pole renal masses from 
posterior aspect. It is usually clinically insignificant and rarely needs treatment. Death following 
renal biopsy is a rare event. Smith et al have published data of about 16,000 cases of abdominal 
fine needle biopsies. They have documented overall mortality rate of 0.031% (53) most 
common causes being hepatic hemorrhage and pancreatitis. This can almost always be 
prevented in all cases of kidney biopsy. Finally, there is no evidence that needle biopsy 
complicates subsequent surgical procedure. There are no studies available to compare the 
complications in US guided versus CT guided biopsies. However under CT guidance, the chance 
of injury to hollow as well as solid viscera is less than 1%. 
 The most disputed possible complication of RMB is the risk of tumor seedling along the 
needle tract. Only 6 cases of possible tumor dissemination from needle biopsy have been 
reported in the literature since 1991. The overall presumed chance of needle tract seedling is 
less than 0.01%. The needle size had no correlation with risk of seedling but the risk increases 
with use of non cutting needles and with the number of needle passes. Furthermore with the 
use of coaxial biopsy technique the chance of tumour seedling are negligible. (Table 3) 
Table 3 
References Needle size Time to presentation Pathological 
finding 
Gibbons et al(65) 18 20 months RCC 
Kiser (66) 14 24 days Papillary RCC 
Shenoy (67) 23 12 months RCC 
Abe and Saitoh (68) 14 18 months Liposarcoma 
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 Transitional cell carcinoma carries a higher risk of seedling than RCC. In cases presence 
of radiological suspicion of a renal pelvic urothelial tumor or positive urinary cytology, 
endoscopic rather than percutaneous biopsy is recommended. 
 
 Another often discussed potential consequence of IGB whether the IGB makes the 
subsequent surgical management difficult or forced us to change our surgical plan. However, 
increasing evidence suggests that previous biopsy does not result in increased surgical 
complications or negatively impact outcomes and should not be used as a reason for avoiding 
IGB (8, 30, 35). 
  
Page | 30  
 
Contemporary indications for renal mass biopsy: 
 The established indications for renal mass biopsy includes patients renal mass and 
known extra renal malignancy, renal mass and febrile UTI to rule out possible abscess, 
suspected case of lymphoma, concomitant with thermal ablation (6, 9). 
 A new, emerging indication includes patients with small [less than or equal to 3 cm] 
solid masses.  Although there may be multiple indications in a given patient, only one indication 
may be needed to proceed with a biopsy. 
 
Absolute indications: 
Renal mass and known extra renal malignancy 
Renal mass and febrile UTI, possible abscess 
Suspected lymphoma 
Concomitant with thermal ablation 
 
Relative indications: 
Mass in a solitary kidney or bilateral renal masses 
Renal mass with imaging features suggestive of unresectable renal cancer 
Medically unfit 
 
Emerging Indications: 
Small enhancing renal masses 
Indeterminate cystic lesions 
Determination of tumor subtype in metastatic setting 
 
 
Patients with imaging findings suggestive of inoperable renal cancer 
 Renal cell carcinoma may be unresectable either due to locally advanced disease or 
distant metastases. In patients with imaging findings highly suggestive of unresectable renal cell 
carcinoma, biopsy is important to establish the diagnosis and offer appropriate treatment. It 
can be performed safely with and has a high sensitivity (54,73). When the tumor is locally 
advanced, the renal mass is the only possible site of biopsy. In case of metastases disease, site 
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of biopsy needs to be decided on the basis of risk-to-benefit analysis so as to get highest yield 
and the lowest risk to the patient. For example, in a patient with renal cell carcinoma with lung 
metastasis, obtaining a biopsy from a possible metastatic deposit to the lung may carry a risk of 
pneumothorax. In such a situation, the biopsy from the renal lesion may provide us better yield 
with less risk to patient. 
Chemotherapy for renal cell carcinoma historically has been ineffective. Immunotherapy 
with cytokines, tyrosine kinase inhibitor or VEGF receptor inhibitor have mixed respond 
depending upon the tumour subtype (74). Newer agents, such as Sorafenib, Sunitinib, target 
vascular endothelial growth factor [VEGF] have been approved for use in metastatic  clear cell 
carcinoma and validated in clinical trials(75,76). For non clear cell subtype recent guideline 
suggest use of mTOR pathway inhibitors like Tamsirulimus. Hence IGB has role in patient with 
unresectable renal primary (76). 
 
Patients with known extra renal primary cancer 
 The commonest malignancies to metastasize to the kidney are lung and lymphoma 
(54,71). Metastatic lesions to the kidney are not rare; autopsy studies demonstrate renal 
metastases in 7-13% of patients with cancer (69,70). The identification of an enhancing renal 
tumour in a patient with an extra renal malignancy poses a diagnostic dilemma regarding 
whether the mass represents a primary renal cell malignancy or a metastatic lesion. Despite 
this high propensity for renal metastases, Rybicki et al (54) demonstrated that 31 of 54 renal 
masses in patients with extra renal malignancies represented renal cell carcinoma. Accurate 
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diagnosis is required because of major treatment implications i.e. most metastatic lesions 
require medical treatment, whereas renal cell carcinomas are resected or ablated. 
 The sensitivity of biopsy in this group of patients has been reported to be 90% (54). 
Although cross sectional imaging showing features such as bilaterality and multiplicity and 
fewer enhancements as compare to surrounding renal parenchyma in most probability point 
out towards metastases, these features can also be rarely seen in patients with renal cell 
carcinoma (50). Cystic masses, however, are unlikely to represent metastases (54). Sánchez-
Ortiz RF et al have suggested that in patients with an extra renal malignancy and no evidence of 
disease elsewhere, a renal mass is almost certainly renal cell carcinoma(72), however, in 
patients with an extra renal malignancy and extra renal metastases, the renal mass cannot be 
assumed to be a metastasis. 
Patients with a solid renal lesion caused by infection 
 Renal infections can have varied radiologic manifestations (77), rarely they may present 
as a tumour-like abnormality and behave like a neoplasm (78). Imaging features such as ill-
defined margins on ultrasound (28) or ill-defined margins, perinephric stranding and patchy 
enhancement on CT (79,80) usually suggest localized infection. An infective pathology can be 
diagnosed with confidence if associated with clinical and laboratory signs of infection. However, 
in absence of  signs and symptoms of a urinary infection (81), a renal mass might be treated as 
tumor  inadvertently. This misinterpretation may lead to surgical resection rather than 
antibiotic therapy. In such small group of patients, in whom a mass-like abnormality may be 
due to an infection, percutaneous biopsy may help to provide the correct diagnosis. 
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Patients with co-morbidities in whom surgery is planned 
 The management of patients with a suspected resectable renal cell carcinoma with 
medical co-morbidities poses a challenging situation for the treating urologist. Co-morbidities 
involves mostly the lung or heart related ailments but can be associated renal insufficiency or 
the presence of mass in a solitary functioning kidney. A formal plan depends not only on 
assessing the surgical and anesthetic risk for the patient. But now with the availability of IGB  
we can safely differentiate renal cell carcinoma from benign neoplasm and avoid unnecessary 
treatment (7,13,17). In cases, where biopsy has provided a definitive diagnosis of RCC, we can 
plan surgery with more confidence (73). 
 
Patients with a small [< 3 cm] hyperattenuating homogenously enhancing renal 
mass 
 Benign non enhancing entities include hemorrhagic or proteinaceous cysts, hematomas, 
vascular anomalies, angiomyolipomas, oncocytomas and rarely metanephric adenoma. The 
malignant lesions include renal cell carcinoma and lymphoma. These benign neoplasms may be 
difficult to differentiate from RCC by imaging alone (83–87). Roughly 5% of AMLs have no 
imageable fat component (12, 83-87) and typically seen on CT as small hyperattenuating 
masses that enhance homogenously (85). In these cases, MR imaging has a peculiar role. MR 
imaging allows differentiation between lipid poor AML and clear-cell carcinoma, which are 
hypointense (85) and hyperintense (88), respectively, on T2-weighted imaging.  
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 The papillary RCC is more difficult to differentiate from lipid poor AML   because it is also 
hypointense on T2-weighted imaging (89,90).  Percutaneous biopsy is therefore required to 
differentiate AML with minimal fat and papillary RCC. 
 
Patients with a renal mass for which percutaneous ablation is considered  
The indications for renal mass ablation are becoming more diverse. Ablation is nephron-
sparing and therefore useful in certain high risk patients including those with bilateral tumors, 
solitary kidneys and in presence of renal insufficiency (91–96). Its use is now advocated in small 
unilateral renal cell carcinomas as an alternative to surgical resection (97). Biopsy of a 
suspected renal cell carcinoma before ablation is imperative because of obvious reasons. In 
surgical resection, whereby the entire surgical specimen can be examined pathologically, 
ablation destroys the neoplasm, and thus no tissue is available for analysis post procedure. 
Therefore, the IGB prior to procedure provides the only opportunity for a tissue diagnosis. 
Furthermore, cross sectional imaging has limitation in differentiating between benign and 
malignant lesion (98, 99). Tuncali et al. (98) demonstrated that 37% of masses referred for 
ablation were benign. Treating a benign lesion with percutaneous ablation has inadvertent 
implications. Not only is the treatment inappropriate and exposes the patient to unnecessary 
risks but the patient is wrongly labeled with a diagnosis of cancer, and subjected to lifelong 
clinical and radiologic follow-up. 
 To validate the technique relative to surgery, the pathology of lesions treated must be 
known prospectively by pre procedural biopsy. Unfortunately several clinical trials of 
percutaneous ablation (93, 95) included renal masses that were diagnosed solely based on 
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imaging. If many of the lesions treated were in fact benign, the efficacy of ablation was 
overestimated. 
 
Indeterminate cystic renal mass 
 The Bosniak classification of cystic renal masses is well established and widely used (1). 
Historically, it has stratified these masses into four broad groups. The chances of getting 
malignancy is  0% in types I , 5% in typed II cyst, about 50% in type III cyst and about 95% in 
type IV cyst(74,100). Hence historically type I and II cyst are considered as nonsurgical lesions 
and types III and IV are typically resected surgically (1).  
 Type III lesions are indeterminate and cannot be definitely diagnosed as benign on 
imaging alone. Although the risk of malignancy is highly variable [31-100%] resection is 
advocated so as not to miss a cancer. Biopsy in this group has been traditionally seen to be of 
limited use as false negative biopsy results are common (1). However, those patients who  are  
not surgical candidates the biopsy may be useful (101). Rybicki et al. have demonstrated a 
sensitivity of IGB to be only 33% whereas Harasinghani et al (102) managed to render a 
diagnosis in 100% of renal cystic lesions. Given this wide spectrum of test performance, biopsy 
is unlikely to become routine in the diagnosis of Bosniak type III cystic lesions. It can be 
considered in patients with surgical co-morbidities. A malignant biopsy result allows surgery to 
proceed with confidence. A negative result may be definitive when a specific entity such as 
oncocytoma or metanephric adenoma is diagnosed. Otherwise, a negative result may provide 
more confidence in following patients. 
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Multiple solid lesions 
 Lymphoma, metastases are the most common conditions associated with multiple solid 
lesions. Clinical history and extra renal findings usually provide the clue to the diagnosis. 
However there are certain hereditary renal cell carcinomas which can result in multiple solid 
renal masses (103). A fine balance needs to be reached between successful eradication of 
tumour as well as preserving functioning renal tissue to avoid dialysis. Nephron-sparing 
techniques such as partial nephrectomy and ablation are often used in combination. Not all 
hereditary syndromes, however, produce malignant masses. Renal oncocytosis results in 
multiple oncocytomas that are benign and do not require treatment (9). Percutaneous biopsy is 
therefore crucial to establish the correct diagnosis before definitive treatment is undertaken 
(103).  
 
Small [3 cm] solid masses 
 The principal criterion for determining the role of biopsy in this emerging indication is 
the size of the solid renal mass. Surgical data have consistently demonstrated that as the size of 
a solid renal mass decreases, the probability of it representing a benign entity increases (41). 
Benign masses most commonly resected include angiomyolipomas with minimal fat, 
oncocytomas, metanephric adenoma, papillary adenoma, and leiomyoma (10,104). These 
masses have historically undergone unnecessary surgical resection because they cannot be 
distinguished from malignant lesions by imaging alone. By performing biopsy of small solid 
renal masses, a significant proportion of benign lesions may be confirmed, obviating the need 
for radical surgeries. Although the size criteria for biopsy in benign etiology is not standardized,  
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biopsy would be more appropriate in smaller masses The masses less than 1 cm are difficult to 
target for biopsy.  
 The increasing treatment of incidentally detected small renal masses is an area of 
continued controversy (106). Mixed results regarding the biologic aggressiveness of small renal 
cell carcinomas with respect to size have been reported(15), However, consensus suggests that 
smaller renal cell carcinomas tend to be of lower grade and more indolent. Co-morbidities, 
patient preference, life expectancy and age are factors that may influence the management. 
The indolent natures of some small renal cell carcinomas have prompted some to consider 
observation in lieu of resection or ablation (107). Percutaneous biopsy can help determine the 
most appropriate management plan by providing information such as cell subtype and Fuhrman 
nuclear grade, which can be used to judge the tumor’s potential for growth and metastases. 
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Pathological advances: 
Advances in cytogenetic techniques, and the discovery of newer markers for identifying 
precise renal tumours, provide distinct advantage for image guided biopsies. [Table 4] (108–
110). These techniques help us to reduce the rate of inderminate biopsies and help us to 
differentiate “oncocytic neoplasms”. 
 The term “oncocytic neoplasm” needs special mention. This group comprises of 
oncocytoma, chromophobe RCC, granular variants of clear cell RCC, eosinophilic variants of 
papillary RCC, and epithelioid AML. Oncocytic neoplasm remains a major diagnostic dilemma in 
the field as a result of overlapping cytomorphology, particularly with the limited pathological 
material obtained from IGB. Beland et al analyzed, inderminate IGB by conventional staining, 
using immunohistochemistry and other ancillary techniques, and provide conclusive diagnosis 
in 89% of cases (53).  
  Liu and Fanning analyzed 18 tumors with FNA, and are able to diagnose oncocytic 
neoplasm 10 patients (28). Of these patients, eight were oncocytomas [80%], one was 
eosinophilic papillary RCC and remaining one was chromophobe RCC on final surgical 
pathology.  Schmidbauer et al (34) also showed similar results suggesting that 10–20% of 
“oncocytic neoplasms” IGB might turn out to be malignant on rigorous pathological analysis. 
IHC  stains that are routinely used appear to have limited success in tumor diagnosis and 
classification in this setting (28,111)and hence there is increasing  use of ancillary studies, such 
as FISH and electron microscopy to improve the diagnostic accuracy for “oncocytic tumors”. 
This has not been routinely incorporated into most of the studies till date (28,111). 
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Table 4 
 
 
Renal cell 
carcinoma 
subtype   
Histology Molecular markers Genetic alterations [Koul et 
al., 2011]127 
Clear cell Nests of tumor cells 
separated by thin 
interconnecting 
vasculature and dilated 
sinusoidal space.Tumor 
cells with clear 
cytoplasm 
[+] GST-α, Vimentin,ADFP, CA-IX,EMA,LMWCK, 
CD10,Caveolin-1,MOC-31,CD26 
[−]:K19,AMACR,Keratin7,CK20,CK7,HMWCK,Ron, 
Parvalbumin 
−3p25, +5q22, −6q, −8p12, 
−9p21, −9q22, −10q, −14q 
Papillary Tumor cells forming 
papillary structures with 
foamy histiocytes 
and hemosiderin. 
[+]:AMACR,CA-IIKeratin7,CD10,CD15,LMWCK 
[−]: GST-α, CA-IX,Ron,Parvalbumin 
+3q, +8, −9p21, +12, −14q, +16, 
+17q21, +20 
Chromophobe Large and polygonal 
tumor cells with finely 
reticulated cytoplasm, 
prominent cell border 
resembling plant cells 
and irregular wrinkled 
nuclei with  perinuclear 
clearing 
[+]: CA-II,Parvalbumin,CD74,Galactin-
3,Cytokeratin 7,Caveolin-1,MOC-31,CK7,E-
cadherin,CD10 
[−]:AMACR,K19,Vimentin,ADFP, HMWCK,Ron, 
CD26 
−5q22, −8p, −9p23, −18q22 
Oncocytoma Nests of tumor cells with 
abundant 
eosinophilic granular 
cytoplasm and uniform 
nuclei. 
[+]: CA-II,Parvalbumin,Ron,Galectin-3,CD10, 
LMWCK, E-cadherin, Caveolin-1, CD26 
[−]: GST-α, AMACR,K19,Vimentin,CD74,HMWCK 
−1p, −8p, −11q13,14q, −19q, 
−21q, −X/Y, 
der[13]t[13;16][p11;p11] 
Angiomyolipoma Classical cases with 
namesakecomponents: 
fat, abnormally formed 
vessels and smooth 
muscle cells. Tumors 
with predominantly 
one element can occur. 
[+]: Melanocytic markers: 
HMB-45 and Melan-A 
[-]: Epithelial markers 
 None 
 
Cost-effectiveness of renal mass biopsy 
 An important consideration in the discussion of renal mass biopsy is the economic 
impact of various treatment approaches. Heilbrun et al estimated that for a hypothetical 
healthy 60 year-old man with a SRM <2 cm, IGB was more cost-effective than immediate 
treatment for quality adjusted-life years gained(97). 
 After considering biopsy performance, the probability of tract seedling, possibility of 
growth of the SRM, treatment costs, patient out- comes, and quality of life, Pandharipande et al 
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(112)  compared IGB to surgery or imaging surveillance. Their Markov model clearly favored IGB 
in term of cost-effectiveness. Thus both these studies argue in favour of IGB when faced with a 
SRM. 
Role of imaging 
 Although most enhancing renal masses are malignant, there are no definitive 
characteristics of a renal mass on CT or MRI that can conclusively distinguish between 
malignant tumors from benign lesions (113). Can we solely depend on imaging information as 
an alternative to biopsy? Can IGB provide superior diagnostic accuracy when compared head-
to-head with imaging?  Dechet et al(60) conducted a study where two radiologists reviewed CT 
scans from 100 patients with a solid renal mass and these results were compared to those of 
pathologists reviewing core samples. Pathologists reviewing core biopsy rates were superior in 
all categories with accuracy rates of 77 and 72%, non-diagnostic rates of 20 and 21%, 
sensitivities of 81 and 83% and specificities of 60 and 33%. Radiologists utilizing CT imaging 
alone could reach to the accuracy rates of 60 and 66% with non-diagnostic rates were 31 and 
23%, sensitivities were 70 and 77% and specificities were 20 and 20% for each radiologist 
respectively.   
 In a retrospective review of 543 patients who underwent surgical excision compared 
pre-operative imaging to final pathology, Dorffner et al found a negative malignancy rate of 
14.7% and  also that the mass size did not predict final pathology with 83% of benign masses 
considered suspicious for malignancy based upon imaging(114). When examining fine needle 
and core biopsies of patients presenting for percutaneous ablation, Heilbrun et al (97) found 
imaging has a positive predictive value of 95% for malignancy but a non-diagnostic rate of 
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11.8%. Unfortunately, there is no study which has head to head comparison between imaging, 
core biopsy and final surgical outcome. Considering the limitations of imaging alone to 
conclusively determine malignancy, it is clearly advantageous to perform IGB. 
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Material and 
methods 
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We have performed image guided biopsy of T1 renal masses and compared its outcome 
with the final histological outcome  
Primary Outcome:  
 To compare imaging guided biopsy outcome with final histopathological outcome like 
pathological finding (malignant/benign lesion), in case of malignancy Furhann’s grade. 
Secondary Outcome/s: 
 Sensitivity, specificity positive predictive value, accuracy in determining the diagnosis. 
 Minor and major complications following the biopsy 
 Age, sex and size stratification of the renal mass, renal nephrometry score and 
correlation of it with the final biopsy. 
Key Criteria 
a. Inclusion Criteria: All patient detected renal mass <= 7 cm. 
b. Exclusion Criteria: 
1. Metastatic disease on presentation 
2. Patient who refuse to give consent. 
3. Patients who have deranged coagulation profile. 
4. Tumour > than 7 cm. 
5. Renal vein, IVC thrombus 
 After institutional review board approval and the patients were recruited to undergone 
image guided percutaneous renal mass biopsy. The patients came for management of detected 
renal mass. Suitability of the patient to include into the study was confirmed as per inclusion 
and exclusion criteria. 
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Before percutaneous biopsy, blood born virus status, the platelet count of >50 
000/mm3 and coagulation profile with normal limit (INR<1.3%) were confirmed.  
Informed written consent was taken prior to biopsy. Details of the consent form were 
given in later paragraphs.     All these patients were admitted for one day prior to biopsy or the 
biopsy is done one day prior to the final surgical procedure.   
       Premedication in the form of inj morphine and inj phenargan were given prior to biopsy 
(According to body weight, single dose, intramuscular). The patient will be placed in the prone 
position, and 1% lignocaine local anesthesia was used. Under Computed tomography guidance 
a coaxial technique was used for biopsy. The coaxial technique limits the number of times the 
renal capsule is violated, and it decreases the risk of bleeding. However, the needle should be 
allowed to move with respiration. Almost all biopsies initially involved core biopsies (2-4 cores) 
when the aspirate sample was sufficiently solid and cellular (usually 17 to 20 gauge. The biopsy 
will be processed by uro pathologist. 
          Post biopsy patient’s vital were monitored at regular interval to rule out any occult 
bleed, trauma to surrounding organs like pleura, liver, colon, spleen. The patients were 
provided analgesics as per need. Those patients who have post biopsy complication will be 
transferred under urology for further management.  
Irrespective of the biopsy report these patient will be offer radical /partial nephrectomy 
to avoid the bias. 
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       The pathological characteristic of the biopsy and the histopathological specimen were 
compared on the basis pathological finding (malignant/benign lesion), in case of malignancy 
Furhann’s classification, immunehistochemistry marker. 
Definition: 
Accuracy: The percentage of informative biopsies for which the pathological diagnosis 
appeared to be correct; that is, based on final surgical pathology  
Biopsy failure was defined as any procedure for which the tumor could not be targeted or 
tumor tissue could not be obtained.  
Indeterminate biopsies included cases in which tumor tissue was obtained, but the pathologist 
could not make a definitive diagnosis and could not differentiate between benign and 
malignant lesion. 
  The sensitivity defined as the number of cancers identified by RMB relative to the total 
number of cancers. 
 The imaging of the renal masses will help in calculating the renal nephrometry score. 
The efficacy of the image guided biopsy in detection of the renal masses will be studied. We 
also stratify the patient according to age, sex and size of tumour and determine   whether these 
factors could predict the pathologic nature of such masses. We have compared the size of the 
mass on imaging with the final biopsy outcome so as identified were the imaging 
overestimated/underestimated the size of mass 
The imaging of the renal masses will help in calculating the renal nephrometry score. 
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The efficacy of the image guided biopsy in detection of the renal masses will be studied. 
We also stratify the patient according to age, sex and size of tumour and determine   whether 
these factors could predict the pathologic nature of such masses. We have compared the size of 
the mass on imaging with the final biopsy outcome so as identified were the imaging 
overestimated/underestimated the size of mass. 
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Proforma 
To study the role of image guided biopsy in management 
of renal masses 
  Patient Details 
1. Name 
2. Hospital number                                                                     
3. Age/Sex 
4. Address 
5. Comorbidities 
 
Investigation: 
1. CT finding  
I. Tumor size 
II. Location  
III. Amenable to biopsy 
IV. Nephrometry score 
 
 
Details of biopsy: 
1. Number of core obtained 
 
2. Post biopsy complication 
 
Minor:  
i. Pain at biopsy site 
ii. Hematoma at biopsy site 
Major:  
I. Profuse  Bleeding that needs further admission and blood 
transfusion 
II. Arterivenous fistula 
III. Pneumothorax, haemothorax 
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IV. Biopsy leading to complication during final surgical procedure 
or change of surgical plan 
V. Death 
 
Biopsy outcome: 
Details of surgery: 
 
I. Initial plan before biopsy:  
II. Change of plan after biopsy: 
III. Time duration of surgery 
IV. Need for Vascular clamping  
V. If clamping done then with or without cold ischemia 
VI. Time of clamping 
VII. Injury to blood vessel 
VIII. Opening of Pelvicalyseal system  
IX. Pleural injury 
X. Peritoeum injury 
XI. Trauma to surrounding organ 
 
 
Final biopsy outcome 
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Results  
Page | 50  
 
The mean age  of the patients was 48 yrs. (median:51 yr; range: 28–83 yr) 
and 4 patients (16%) were women. 84% percent of renal tumors did not have 
symptoms pertaining to renal masses. 84% patients had at least one co 
morbid factor listed in the table. Two patients had multiple tumours and 
one patient had bilateral tumors. 14 renal tumors were located in the left   
kidney (56%).  ( T a b l e 5 ) .  
Table  5                                                      Demographic profile 
Total patient   25  
Mean Age   48.8 yr  
Sex  Male  21  
 Female  4  
Side  Left  14  
 Right  11  
   
Co morbidities  DM  8  
 HT  11  
 CKD  4  
 Other  13  
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Presentation Non specific Flank pain 4 
 Hematuria 4 
 Other  3 
 Incidentally detected during 
routine evaluation 
14 
 
 Mean tumor diameter on preoperative C T  scan was 4.1 cm (median: 
3.2 cm;  range: 2.2 - 7 cm);  A b o u t  6 8 %  t u m o u r s  h a d  s i z e  l e s s  t h a n  e q u a l  t o  4  
c m .  P o s t  o p e r a t i v e l y  h o w e v e r  a b o u t  8 8 %  t u m o u r s  w e r e  r e p o r t e d  a s  p T 1 a  
s u g g e s t i n g  t h a t  t h e  C T  o v e r e s t i m a t e s  t h e  s i z e  o f  t u m o u r .  W e  f a i l e d  t o  
i d e n t i f y  a n y  c o r r e l a t i o n  n e p h r o m e t r y  s c o r e  w i t h  c o r e  b i o p s y  e x c e p t  t h a t  
3  o f  t h e  6  p a t i e n t s  w h o m  r a d i o l o g i s t  r e f u s e d  t o  d o  b i o p s y  w e r e  i n  
a n t e r i o r  l i p .  ( T a b l e  6 ) . A flowchart of the results of core biopsy is shown in table 7. Out 
of the 25 core biopsies, 20 biopsied showed RCC, which also correspond to final histological 
outcome. 3 patients were reported to have hybrid oncocytic variant, out of which 2 patients 
had oncocytoma and the third one turn out to be chromophobe RCC.  2 samples were 
inadequate for interpretation; the final histopathology revealed lipid poor angiomyolipoma 
and clear cell RCC respectively. (Table 7)Out of 25 core biopsies, 22 patients had malignancy in 
final histological outcome.1 core biopsy which was inadequate for reporting was found to have 
RCC. Out of the three patients in whom core biopsy revealed hybrid tumour, one was 
eventually found out to be chromophobe RCC. 
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T a b l e  6  Biopsy  
Mean CT  size 4.1 cm 
(median: 3.2 cm;  range: 2.2 - 7 cm) 
CT size                                             T1a 
                                                          T1b 
17(68%) 
8 (32%) 
Final histopathology                        T1a 
                                                            T1b 
22 (88%) 
03 (12%) 
Multiple tumour  2 
Bilateral tumour 1 
T a b l e  7
 
25 biopsies
23 adequate 
sample
Clear cell
18
Papillary cell 2
Oncocytolitic
variant
3
2 inadequate 
sample
Low fat 
Angimyolipoma
1
Clear cell 
Carcinoma 1
Chromophobe
RCC 1
Oncocytoma 2
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Considering this about 2 out of 22 patients might have been missed if biopsy was considered as 
final criteria.  
Table 8 
 
Malignant  
Insufficient  2(25)  
Detection of malignancy (accuracy) 100% 
True-positive, n  20  
False-negative, n  1 
False-positive, n  0  
True-negative, n  2 
Sensitivity 95%  
Specificity 100% 
PPV 100  
NPV 66%  
Accuracy for RCC Subtype  91%  
Fuhrman grade  75%  
 
Sensitivities, specificities, PPVs, and NPVs for the detection of RCC core biopsy are 
shown in table 4. Out 0f the 20 patients where biopsy revealed RCC, subtype was correctly 
predicted in 100% patients. However the accuracy for the differentiation of Fuhrman grade was 
75% of biopsies using core biopsy. The incorrect grade was identified using core biopsy in 25 % 
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(n = 5). Core biopsy failed to identify Fuhrman grade 3 in 1 patients and rest 4 patients the core 
biopsy grade was grade I, however the final histological outcome showed Fuhrman grade II. 
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Discussion 
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 As earlier mentioned, RMB is usually carried out using an 18-gauge needle to optimize 
the cellular yield without increase patient morbidity. For tumour less than 4cm, it is 
recommended to take 2 biopsies from central and peripheral zone. For tumours more than 4 
cm especially if there is presence of central necrosis two to three peripheral biopsies are 
advocated as standard protocol. Cores should be visually assessed for size and quality. If the 
cores appear fragmented or particularly small [<1 cm] additional biopsies should be taken. (35). 
Samples can be used to extract genetic material for genomic analyses.(33) .Although there is no 
randomized prospective data, most author’ experiences suggest that the use of an 18-gauge 
needle improves biopsy yield relative to FNA(24). 
In this study biopsies were performed with co axial technique using 17 G cannula and 
18G tru cut biopsy gun. We are able to obtain average 3.6 adequate cores per biopsy.  We 
have noticed that with the above protocol we are able to get adequate tissue in about 92% 
cases. Breda et al. carried out ex vivo RMB and found that an 18-gauge needle [or larger] was 
most accurate in determining histological diagnosis (45) and  Schmidbauer et al. reported 
similar findings related to their in vivo study(35) 
  Renal mass biopsy is most often done under image guidance. Each modality (US, CT) 
has its own distinct advantages related to tumor location, body habitus and other important 
considerations. The potential disadvantages of US include the inability to differentiate isoechoic 
renal masses from normal renal parenchyma, distinguishing adjacent pleural folds and bowel. 
Technical difficulties include biopsying in the obese population. (113) 
All these problems can be avoided using CT fluoroscopy. The advantages of CT guidance 
are that 1] gas and other structures do not obscure visibility, 2] there is excellent spatial 
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resolution, 3] there is better needle visualization, 4] it is easier to avoid necrotic areas and 5] 
there is more rapid skill acquisition. 6] It also provides a higher resolution image and thereby 
facilitates the avoidance of adjacent vital structures and necrotic areas at the time of sampling. 
Table 9 
Reference No of 
tumours 
No 
pathological 
confirmation 
Radiological 
surveillance 
No of 
Cancer 
biopies Guidance Complication 
     Needle 
Size 
No of 
sample 
 Minor Major 
Vasudenvan(52) 100 48(48%) 43(43%) 51(51%) 16G NA CTorUS 0 1 
Beland(53) 58 8(13.8%) 45(77%) 39(67%) Varied NA CTorUS 0 0 
Volpe(49) 100 21(21%) 79(79%) 67(67%) 17Gcannula 
18Gbiopsy 
NA CTorUS or 
both 
3 0 
Masoom(40) 31 31(100%) 0 28(90%) FNA NA  NA NA 
Schimidbauer 
(34) 
78 78(100%) 0 65(83%) 18G and 
FNA 
2-3 CTorUS 1 0 
Maturen (116) 152 87(57%) NA 87(57%) 18G 3-4 CTorUS 1 2 
Present study 25 25(100%) 0 23(92%) 17Gcannula 
18Gbiopsy 
2-3 CT 8 1 
  
In the present study all the biopsies were done under CT guidance. We are able to 
obtain adequate sample in 92% cases (Table 9). By using CT fluoroscopy, which allows biopsy 
gun activation in real-time mode, Neuzellet et al (35) discovered that in some cases the needle 
pushes the tumor instead of penetrating it. This phenomenon could explain the high failure rate 
in small tumors observed in studies where fluoroscopy is not used. Schimidbauer(34) et al 
reported a study on 78 patient who underwent biopsy followed by surgical extirpation. The 
patient underwent FNA and biopsy both before surgery. The imaging modalities used however 
was not uniform. 
 Post RMB complications are always been unreported or less reported. However in 
general the complication rate is less than 1%. We have used the norms of The Society of 
Interventional Radiology for reporting the complication. Complications are classified into minor 
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or major depending on patient outcome. Minor complications are defined as those that require 
no or nominal therapy, including overnight hospital admission for observation only. Minor 
complication of CT guided biopsy are includes biopsy site pain, localized skin hematoma. Major 
complications are those that require therapy or longer hospitalization, or lead to permanent 
adverse sequelae or death. In the present only patient required change of original surgical plan 
because of perinephric adhesion and hematoma.5 of the 7 patients reported biopsy site pain 
Table 10 
Reference 
No. 
No. 
tumo
rs 
biopsy 
failure 
(%) 
No. 
indeterminate 
(%) 
No. biopsy 
non-
informative 
(%) 
No. false 
negatives 
(%) 
No. false 
positives 
(%) 
 
No. accurate†/Total No. (%) Sensitivity 
for 
malignancy 
(%) 
       Malignant 
vs benign 
Histology Grade  
Vasudevan 
et al. (2006) 
(52) 
100 NA NA 29(29%) 0 0 71/71 
(100) 
44/44 
(100)  
NA 43/51(84.3%) 
Beland et 
al.(2007) 
 (53) 
58 3(5.2) 3(5.2) 6 (10.4%) 1 (1.9%) 0 51/52 
(98%) 
NA NA 38/39(97.4%) 
Schmidbauer
et al. (2008) 
(35) 
78 0 2 (3%)   2(3%) 3 (3.8%) 0 73/76 
(96.1%) 
59/60 
(98.3%) 
44/58 
(76%) 
60/65 
(92.3%) 
Volpe et al. 
(2008(49) 
 
100 8 (8%) 8 (8%) 16 (16%) 0 0 84/84 
(100%) 
56/60 
(93%) 
for RCCs 
41/60 
(68%)  
66/67 
(98.5%) 
Masoom et 
al. (2009 )  
(40)     
  
31 0 0 0 0 1 (3.2%) 
 
30/31 
(96.7%) 
28/29 
(96.6%) 
NA 28/28 (100%) 
Present 
Study 
25 2 3 0 1(4%) 0 22/25 
(88%) 
22/25 
(88%) 
15/20 
(75%) 
95% 
   
with 1 patient developed localized hematoma at biopsy site. 1 patient required admission for 
more than 24 hrs for monitoring. 
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Sensitivities, specificities and diagnostic accuracy: 
Since our entire patients underwent surgical extirpation irrespective of biopsy outcome, 
the data comparing the biopsy outcome with final histopathological outcome is more reliable. 
Most of the studies mentioned in the table 10 are on active surveillance hence these studies 
actually compare the biopsy outcome with radiological imaging. This is a major confounding 
factor in interpretation of these studies.  
 Advances in cytologic techniques, have contributed to the increasing ability to 
differentiate between benign and different RCC subtypes using percutaneous renal tumor 
biopsy .The sensitivities, specificities, PPVs, and NPVs of FNAC and core biopsy for the detection 
of RCC found in the current study are at the higher end of reported series.(table 10). Overall, 
most studies have been retrospective, with highly selected patient cohorts and no standardized 
biopsy protocols. The reported sensitivity of biopsy for the diagnosis of malignancy ranges from 
80% to 92%, regardless of the needle size used or whether the specimens were examined 
cytologically, histologically, or both (116). False-negative results are most often due to a failure 
to place the needle tip accurately in a small mass. In the current study only about 8% of 
percutaneous biopsies showed false-negative results. In the retrospective study by Maturen et 
al, 4% of biopsies were nondiagnostic, and 5% of samples overall were inconclusive in the 
series. 
Exciting advances in immunocytogeneticsand the emergence of reliable markers for 
identifying specific renal neoplasms, hold great promise for image guided biopsies.(117). These 
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analyses have the potential for reducing the incidence of non-informative biopsies and 
providing increased differentiation of “oncocytic neoplasms” 
  One example of this is the study from Beland et al who analyzed RMS that were non-
informative by conventional hematoxylin–eosin staining alone, and reported a definitive 
diagnosis in 89% of cases with the addition of immunohistochemistry and other ancillary 
techniques. (53). The major diagnostic challenge is represented by oncocytomas. Oncocytic 
cells are found in numerous RCCs, such as chromophobe RCC, the granular cell variant of RCC, 
and the eosinophilic variant of papillary type RCC (type 2). Immunocytochemistry can help to 
distinguish between RCC and oncocytomas. In this series, only 2 of the 3 patients in whom 
oncocytic neoplasm was diagnosed on IGB, final histopath came as oncocytoma biopsies. 
There was possibility of missing one chromophobe RCC if we have not offer surgical 
extirpation irrespective of biopsy report.  Angiomyolipomas are considered difficult to identify 
on biopsy due to nuclear atypia and pleomorphism comparable to those found in RCC (117). 
However HMB-45 is constantly expressed by angiomyolipomas but not by RCC or liposarcomas. 
Additionally, angiomyolipomas are negative for cytokeratin (118). In this study so far we have 
seen only one lipid poor angiomyolipoma in which the IGB was non informative. The series of 
Neuzillet et al (35) included 10 oncocytomas, three angiomyolipomas, and one cystadenoma. 
 We are able to diagnose subtype of renal cancer in 20 of the 22 patient.(90%).  Barocas 
et al (43) was able to improve the accuracy of sub typing from 90% to 95% by adding molecular 
diagnosis (in which RNA from core biopsies was extracted and quantitative 
real-time polymerase chain reaction performed for four gene products to differentiate 
RCC subtypes) to histopathologic diagnosis. Subtypes of RCC have distinct cytogenetic 
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abnormalities, such as the loss of 3p in clear-cell, trisomy 7 or 17 in papillary, and widespread 
chromosomal losses in chromophobe RCC (24, 35, 53).  In a recent study by Gowrishankar 
B(119) et al lends support for a role of a novel FISH assay to assist in the yield and accuracy of 
diagnosis of renal cortical neoplasms in needle biopsies, in particular to help guide clinical 
management of patients with SRMs that were non-diagnostic by histology. 
 Sensitivity is lower than the figures quoted for “accuracy”, because it takes into account 
non-informative biopsies that failed to diagnose the malignancy. The accuracy quoted in many 
recent studies is unrealistically high. The sensitivity of contemporary RMS series ranges from 
84.3% to 100% [Table 10].  Positive predictive value is extremely high in these series as 
reflected by the very low false-positive rate. Hence, a diagnosis of cancer can be relied on and 
will almost always be confirmed as malignant on final surgical pathology. The present study 
showed the accuracy, sensitivity and positive predictive value to diagnose malignancy were 
100%, 95% and 100% respectively. 
 Data about negative predictive value must be considered limited, because most patients 
with a benign diagnosis on RMS do not proceed to surgery. We have found the negative 
predictive value to be somewhat low to about 66%. This is because of failure to differentiate 
chromophobe RCC from oncocytoma. Data from the Liu et al (28) study indicates that this will 
be approximately 80–90%. Specificity is often discussed in the RMS literature, but again, 
conclusions about this should be restricted as a result of the lack of surgical confirmation in 
most studies.  
 In summary, the RMS literature to date has been compromised by ambiguous 
terminology, as well as unclear and at times inappropriate definitions. Quoted “accuracy” rates 
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may be artifactually high, as RMS is still challenged with major concerns with respect to 
sampling error, tumor heterogeneity, and presence of “oncocytic neoplasm”. Sensitivity and 
positive predictive value remains very high overall, and most importantly, false negative rates 
are almost negligible, which has great clinical relevance. Non-informative biopsies still 
represent 10–20% of all RMS, although with appropriate recognition, they can be managed in a 
sensible manner. 
Accuracy of tumor grade and subtype 
 As experience with image guided biopsies is increased, so has interest in the grading of 
biopsies, because this may have implications for tumor management by stratifying tumor risk. 
Concordance rates between biopsy specimens and final surgical pathology range from 46% to 
94% for Fuhrman nuclear grade,(33,34,54,58). Although most discordant cases are only one 
grade off.  In Lebret study concordance was increased to 7% by compressing the classification 
to “low” and “high” grade, which is likely to have clinical relevance. This divergence may be a 
result of both inter observer variability and tumor heterogeneity. The significance of this 
becomes apparent with the increasing use of active surveillance and ablative therapies, which 
generally should not be utilized in the setting of a high-grade cancer, regardless of size. (59) 
In the present study the concordance between the core biopsy to final histology is 75%. Most 
of the divergence in nuclear grade is by 1 grade. It is also noticed the present study that 
probability  of reporting low grade in high grade tumour is less than vice versa.  
  Neuzillet et al (35), investigating 88 biopsies performed with CT guidance and 18-gauge 
needles in small solid masses, reported a concordance of Fuhrman nuclear grade in 
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percutaneous biopsy and histopathologic specimens of only 69.8%. In our study the accuracy 
for detecting high and low Fuhrman grade was 75%.  Because Fuhrman grade is a prognostic 
marker, improvements are needed for a better classification of nuclear grade on biopsy 
specimens. 
As secondary outcome we tried to see if any there is correlation between renal 
nephrometry score and biopsies, but we failed to identify any concrete correlation.  
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Conclusion 
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The role of RMB in the setting of T 1 renal masses is expanding. Approximately 12% of 
renal masses removed by surgical excision have benign pathology hence surgery can be safely 
differed if we know pathology beforehand using IGB. 
We are able to obtain average 3.6 adequate cores per biopsy.  We have noticed that 
with the above protocol we are able to get adequate tissue in about 92% cases. 
The present study showed the accuracy, sensitivity and positive predictive value to 
diagnose malignancy were 100%, 95% and 100% respectively. We are able to diagnose subtype 
of renal cancer in 20 of the 22 patient (90%).  
Since we have compared the biopsy outcome with final histological outcome the 
negative predictive value and specificity has more importance. We have found the negative 
predictive value and specificity to be 66% and 100% respectively. Ongoing research continues 
to show promise in the development of molecular, cytologic and histologic markers to further 
characterize renal masses. It might help us in determining optimal immunotherapy in future or 
targeted systemic therapy susceptibility, predict tumor behaviour and outcomes and discover 
new pathways in renal tumor biology.  
In the present study the concordance between the core biopsy to final histology is 75%. 
Most of the divergence in nuclear grade is by 1 grade. It is also noticed the present study that 
probability  of reporting low grade in high grade tumour is less than vice versa. Clinicians can 
increasingly risk-stratify patients based upon RMB results, leading to important decisions such 
as whether to excise the tumor, likely safety of active surveillance. 
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Post procedure complications are relatively uncommon, encouraging us for its wider 
adoption.  
If IGB is incorporated in the routine evaluation, physicians will become increasingly 
skilled at this procedure, thereby decreasing failed biopsy rates.  
With this ever increasing data on the usefulness of RMB, it may be time to increase 
utilization as part of routine practice in the management of the renal masses.  
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name hospital numberag sex side comorbiditysymptoms CT finding number of core obtained Biopsy outcome post op biopsy outcomeost biopsy complicationDetails of surgical procedure post operative details
mantosh Debnath494728f 58 m left 1,2 2 2.2 interpolar 1 2 clear cell carcinoma clear cell grade 3 2.2 cm no LVI1 1--4 2 180 3 3 3 0 0 0 0 0 150
geeta bauri391977f 49 m right 6 1 2.3 interpolar 1 6a 2 tissue inadequate oncocytoma1,2 1 2 140(18) 1 2 0 0 0 0 ###0 100
prakash sinha663308f 83 m left 2 4 2.4 lower 1 5x 2 inconclusive oncocytoma 4 cm 1 1 2 130 2 2 0 0 2 3 200
shyamlal saha438516f 45 m right 0 2 2.6 lower 1 6x papillary cell papillary grade 1 2.6 cm no LVI1,2 02----01 1 120 3 3 0 1 0 0 0 500
abdul samad376787f 47 m left 1,9 2 3 lower 1 4a 2 clear cell grade 1 clear cell grade1 3.5 and 1.9 no LVI1,2 1 2 195(45) 1 1 1 0 0 0 500
Askok kumar datta274469f 59 m left 0 2 3 interpolar 1 9a not conclusive inadequate specimen chromophobe   2cm no LVI1,2 1 2 250(20) 1 2 2 1 1 0 600
gita devi 317158f 45 f right 5,6 4 3.2 upper 1 8a 3 clear cell grade 1 clear cell grade1 3.5 no LVI1 1 1 270(39) 1 1 0 1 0 0 1(500)
prem kumar rai267450f 52 m left 2 2 3.3 lower 2 5x clear cell grade 2 4cm no LVI 1 90 2 3 0 0 0 0 0 100
Raja A M 059447a 57 m right 1,2,5 1 3.3 upper 1 4x clear cell grade 2 clear cell grade 3.2cm no LVI1,,2 1 2 180 2 3 0 0 0 0 0 800
Deepamani majumdar701258f 29 m right 1 3.5 1 7a 4 clear cell grade 1 clear cell grade 2  3.7 no LVI1,2 1 2 180(35) 1 1 1 0 2 3 1(750)
md issaq chaudhary628763f 54 m left 1 1 3.5 lower 1 6p 2 papillary cell papillary grade 2 3.2 no LVI1 1--2 2 130(40) 1 2 0 0 0 0 0 900
mohd Belal488504f 30 m right 2 2 3.6 lower 1 6p 2 clear cell grade 1 clear cell grade 1 3.6cm no LVI1,2 4 2 120 3 3 0 0 0 0 0 100
balasubramianum887531d 53 m right 1 1 3.8 interpolar 1 9x 2 clear cell grade 2 clear cell grade 3  4 no LVI1,2 4 0 150 3 3 0 0 0 0 500
sayed iqbal quraishi475130f 35 m left 0 2 4 upper 1 8p 3 clear cell grade 1 clear cell grade 3 4cm no LVI1,2 1 2 240(20) 1 1 0 0 1 0 0 2(2000)
sunil baran mahato800764f 36 m left 0 3 4 upper 1 6x 3 TCC 1 4 2 180 3 3 0 0 0 0 0 100
anaanda rishnan218713f 40 m right 0 2 4.5 upper 1 6p 2 clearcell grade 1 clear cell grade  2 4 no LVI1,2 2 2 240(23 warm) 2 2 0 2 0 0 0 600
anti pathak433164F 53 f left 1 4.8 interpolar 1 10 x clear cell grade 1 clear cell grade 1 5.7 no LVI1,2 1 1 135 0 0 0 0 0 0 0
sultan Ahmad30569c 59 m right 1,2 5 5 lower 1 8x 2 clear cell grade 1 clear cell grade 2 4.5  no LVI1 1 2 150(40) 1 1 0 1 0 0 0 200
Md  Moiz Arif221931f 34 m left 0 3 5.1 lower 1 2 clear cell grade 1 clear cell grade 2 5 cm no LVI1 1 2 210(40) 1 1 0 1 1 0 0 400
sartha 308238f 28 f left 0 1 5.2 interpolar 1 7x angiomylolipoma
pradeep singh679981f 38 m right 0 1 6 lower 1 9x chromophobe grade2 chromophobe grde 1   6 cm no LVI1,2 1 2 180(20) 3 3 0 1 1 0 800
gopal chandra673993f 53 m left 2,5 1 6 interpolar 1 9x 1 clear cell carcinoma clear cell grade 2 6cm no LVI0 1 2 120(10) 1 2 0 1 1 0 200
karti chandra ghosh742103f 60 m right 0 3 6 interpolar 1 11x 3 papillary grade 1 papillary grade 2 6 cm no LVI1 4 2 120 3 3 0 0 0 0 0 50
parul sarkar106851f 74 m left 0 1 7 lower 2 10x clear cell grade 2 6.5 cm no LVI4 2 150 3 3 0 0 0 0 0 0 100
george verghese709647f 54 m right 2 1 4,2 interpolar 1 6a,5a 3 clear cell grade 2 clear cell grade 2  4 ,2 no LVI1 1 240(20) 1 1 1 0 2 0
1 OPN 1 yes 1 yes 1 cold 1 yes 1 yes 1 plura 1 yes uneventful   0 1  yes
DM 1 1 icidental 1 yes 2  LPN 2 no 2no 2 warm 2no 2no 2 peritoneum2no ICU    vasopressor  1 2    no
HT 2 2 flank pain 2 no 3 ORN 3 not required3 not clamped0 not required0 not required0  no 0 not requiredICU   ventiltion  2 0 not required
COPD3 3 hematuria 4 LRN ICU monitoring 3
CAD 4 4 other symptoms
CKD 5 5 LUTS
anaemia 6
Other  9
1    Pain at biopsy site
2   Hematoma at biopsy site 
3  Profuse  Bleeding that needs further admission and blood transfusion
4     Arterivenous fistula 
5  Pneumothorax, haemothorax
6     Biopsy leading to complication during final surgical procedure
